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OBJECTIVE: We refer to the effectiveness (known as pragmatic or real world) and efficacy (known as
explanatory or desired or ideal world) of interventions. However, these terms seem to be randomly chosen by
investigators who design clinical trials and do not always reflect the true purpose of the study. A pragmatic-
explanatory continuum indicator summary tool was thus developed with the aim of identifying the
characteristics of clinical trials that distinguish between effectiveness and efficacy issues. We verified whether
clinical trials used the criteria proposed by the indicator summary tool, and we categorized these clinical trials
according to a new classification.
METHOD: A systematic survey of randomized clinical trials was performed. We added a score ranging from 0
(more efficacious) to 10 (more effective) to each domain of the indicator summary tool and proposed the
following classifications: high efficacy (o25), moderate efficacy (25-50), moderate effectiveness (51-75), and
high effectiveness (o75).
RESULTS: A total of 844 randomized trials were analyzed. No analyzed trials used the criteria proposed by the
indicator summary tool. Approximately 44% of the trials were classified as having moderate effectiveness, and
43.82% were classified as having moderate efficacy.
CONCLUSIONS: Most clinical trials used the term ‘‘efficacy’’ to illustrate the application of results in clinical
practice, but the majority of those were classified as having moderate effectiveness according to our proposed
score. The classification based on the 0-100 score is still highly subjective and can be easily misunderstood in all
domains based on each investigator’s own experiences and knowledge.
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’ INTRODUCTION
Clinical trials produce the best data available for health care
decision making, as they use a prospective design, follow a
process of randomization (patients are allocated at random to
receive one of several clinical interventions) and seek to measure
and compare the outcomes of two or more clinical treatments.
The randomized clinical trial (RCT) in particular is one of the
most simple, powerful and revolutionary tools in research (1).
When discussing treatment and examining evidence, we
refer to effectiveness (known as pragmatic or management
related; treatment that works under real-world conditions)
and efficacy (known as explanatory; treatment that works
under ideal conditions) (2,3). However, these terms seem
to be randomly chosen by investigators who design
clinical trials and do not always reflect the true purposeDOI: 10.6061/clinics/2015(09)04
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of the study. In addition, renowned educational institu-
tions involved in evidence-based medicine disseminate
vague definitions of these terms (2,3), as described in 1967
by Schwartz (4).
A pragmatic-explanatory continuum indicator summary
(PRECIS) tool (5) was developed in 2009 with the aim of
identifying the characteristics of clinical trials that distin-
guish between effectiveness and efficacy issues and assisting
researchers in preparing their clinical trials. It is important to
note that according to PRECIS (5), the classification of a
clinical trial is not a dichotomy, i.e., there is a gradient
between effectiveness and efficacy. Therefore, it is very
difficult to conduct (and hence categorize) a clinical trial as
‘‘purely’’ one of effectiveness or ‘‘purely’’ one of efficacy.
However, it is unclear whether investigators designing
clinical trials use PRECIS (5) to assist policy makers and
health professionals with trials’ results in policy and clinical
practice. Additionally, it is unclear whether the PRECIS tool
would be adequate to classify trials into real- or desired-
world categories.
Therefore, we i) verified whether clinical trials published
in the last three years used the criteria proposed by PRECIS
(5); ii) determined whether the clinical trials’ authors made
appropriate use of the terms ‘‘effectiveness’’ and ‘‘efficacy’’
according to a proposed 0-100 scale, called the Grading of
Efficacy-Effectiveness in Clinical Trials (GEECT); and iii)
classified the clinical trials according to the GEECT classifica-
tion (i.e., high or moderate efficacy, high or moderate
effectiveness).
’ METHODS
Overall study design
In this systematic survey, we randomly selected full
reports of randomized clinical trials (RCTs) published in
journals that were chosen based on their importance to
clinical practice. Table 1 shows the list of journals analyzed
and their respective percentages, which were considered in
our clinical trial search strategy.
Eligibility criteria
The inclusion criteria were as follows:
 RCTs published in full-text in one of the selected journals
(Table 1) and
 RCTs mentioning the terms ‘‘effectiveness’’ and/or ‘‘effi-
cacy’’ in either the title or the objectives section.
The Grading of Efficacy-Effectiveness in Clinical
Trials (GEECT) tool
We added a score ranging from 0 (more efficacious) to 10
(more effective) to each of the 10 domains of the PRECIS
(5) tool (i.e., eligibility criteria for trial participants,
flexibility with which the experimental intervention is
applied, degree of practitioner expertise in applying the
experimental intervention, flexibility with which the
comparison intervention is applied, degree of practitioner
expertise in applying the comparison intervention, follow-up
of trial participants, trial’s primary outcome, participants’
compliance with the prescribed intervention, practitioners’
adherence to the study protocol, and analysis of the primary
outcome), which together determine the extent to which a trial
is effective or efficacious, and we named it the GEECT tool.
We then created a classification, with definitions ranging
from high efficacy (HEcy) to high effectiveness (HEss), as
shown in Table 2. The terms ‘‘effectiveness’’ and ‘‘efficacy’’
were defined according to the PRECIS (5) tool.
The agreement variable ‘‘Is the term used correctly?’’ was
related to the concordance between the terms ‘‘efficacy’’ and/or
‘‘effectiveness’’ used by an RCT’s authors and the GEECT
classification, as ranked by the investigators of the present
study using the GEECTscore. For example, if an RCT’s authors
used the term ‘‘efficacy’’ and the GEECT classification fell into
either the HEcy or moderate efficacy (MEcy) category, we
answered ‘‘yes, the term was used correctly’’ for this question.
In contrast, if an RCT’s authors used the term ‘‘efficacy’’ and
the GEECT classification fell into either the HEss or moderate
effectiveness (MEss) category, we answered ‘‘no, the term was
not used correctly’’ for this question. Finally, if an RCT’s
authors used both ‘‘efficacy’’ and ‘‘effectiveness,’’ we consid-
ered the use of both terms in their published papers.
Selection of studies
We searched studies published between 2009 and 2012 in
each chosen journal using a comprehensive search strategy,
including an exhaustive list of synonyms for clinical trials
and the words ‘‘effectiveness’’ and ‘‘efficacy.’’ This search
was specifically conducted by a librarian.
Table 1 - List of the journals analyzed and their respective
percentages.
Journal’s name Number (%)
New England Journal of Medicine 121 (14.34)
The Lancet 83 (9.83)
Cancer 75 (8.89)
JAMA: The Journal of the American Medical Association 55 (6.52)
The Clinical Journal of Pain 51 (6.04)
Ophthalmology 44 (5.21)
Archives of Internal Medicine 32 (3.79)
Clinical Infectious Diseases 31 (3.67)
Circulation 29 (3.44)
The Journal of Pediatrics 28 (3.32)
British Journal of Anaesthesia 27 (3.20)
American Journal of Respiratory and Critical Care Medicine 26 (3.08)
European Urology 26 (3.08)
Anesthesiology 21 (2.49)
European Journal of Heart Failure 21 (2.49)
American Journal of Ophthalmology 20 (2.37)
Transplantation 20 (2.37)
Annals of Surgery 15 (1.78)
The European Respiratory Journal 13 (1.54)
Thorax 13 (1.54)
Annals of Neurology 10 (1.18)
Hypertension 9 (1.07)
The American Journal of Medicine 9 (1.07)
BMJ: British Medical Journal 6 (0.71)
Archives of Surgery 6 (0.71)
Journal of Clinical Epidemiology 6 (0.71)
American Journal of Surgery 5 (0.59)
Critical Care Medicine 5 (0.59)
Occupational and Environmental Medicine 5 (0.59)
The American Journal of Surgery 5 (0.59)
Diabetes 4 (0.47)
Journal of Epidemiology and Community Health 4 (0.47)
Science 4 (0.47)
Journal of Internal Medicine 3 (0.36)
Kidney International 3 (0.36)
American College of Physicians 2 (0.24)
Annals of Internal Medicine 2 (0.24)
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Data extraction
Phase 1 consisted of brainstorming and conducting
practical exercises with all of the investigators involved in
the data extraction via weekly meetings over eight months.
Phase 2 comprised a pilot study, with all of the investigators
scoring the same RCT according to the GEECT classification.
Statistical analysis
We randomized 47 clinical trials for consistency checking
by two randomly chosen investigators and calculated the
inter-observer agreement rate using the kappa test in relation
to the GEECT classification. We expressed each domain as
the mean and standard deviation (SD). The overall mean and
SD from each investigator’s data were used. The percentage
of the GEECT classification (i.e., HEcy, MEcy, MEss and
HEss) was also calculated. Proportional tests were conducted
to compare MEcy and MEss as well as HEcy and HEss. The
results were considered significant when p was o0.05. We
used SPSS software version 12.0.
’ RESULTS
A total of 1,039 references were identified. From this total,
844 RCTs met the inclusion criteria and were analyzed by 19
investigators from different areas of expertise. Therefore,
each investigator analyzed approximately 44 clinical trials in
duplicate and independently. The remaining studies were
generally excluded because the terms ‘‘effectiveness’’ and/or
‘‘efficacy’’ were found in either the discussion or the
reference section.
The studies were published in a wide variety of journals
(33 journals), with 14.34% in the New England Journal of
Medicine, followed by 9.83% in The Lancet and 8.89% in the
Journal Cancer (Table 1).
The inter-observer agreement for the GEECT categories
classified as HEcy, MEcy, MEss and HEss was slight (kappa
coefficient: 0.11) for the two investigators.
No clinical trials published in the selected journals in the
last three years used the criteria proposed by PRECIS to
differentiate between effectiveness and efficacy.
The statistics relating to the 10 domains, ranging from 0
(more efficacious/ideal/desired) to 10 (more effective/real),
that were found in the RCTs and analyzed by the 19
investigators are shown below as the mean (SD):
4.98 (1.47) - all participants who have the condition of
interest are enrolled, regardless of their anticipated risk,
responsiveness, comorbidities or past compliance;
4.08 (1.45) - instructions on how to apply the experimental
intervention are highly flexible, offering practitioners con-
siderable leeway in deciding how to formulate and apply it.
5.50 (1.82) - the experimental intervention is typically
applied by the full range of practitioners and in the full range
of clinical settings, regardless of expertise, with only ordinary
attention to dose setting and side effects.
4.14 (1.30) - ‘‘usual practice’’ or the best alternative
management strategy available is recommended, offering
practitioners considerable leeway in deciding how to apply it.
5.77 (2.06) - the comparison intervention is typically
applied by the full range of practitioners and in the full
range of clinical settings, regardless of expertise, with only
ordinary attention to practitioner training, experience and
performance.
4.53 (1.85) - no formal follow-up visits with study
individuals are performed. Instead, administrative databases
(e.g., mortality registries) are searched for the detection of
outcomes.
5.70 (2.00) - the primary outcome is an objectively
measured, clinically meaningful outcome for the study
participants. This outcome does not rely on central adjudica-
tion and is one that can be assessed under usual conditions
(e.g., special tests and training are not required).
5.44 (1.98) - there is unobtrusive (or no) measurement of
participant compliance. No special strategies to maintain or
improve compliance are used.
5.30 (2.34) - there is unobtrusive (or no) measurement of
practitioner adherence. No special strategies to maintain or
improve practitioner adherence to the study protocol are
used.
6.38 (1.82) - the analysis includes all patients, regardless of
compliance, eligibility, and other factors (such as intention-
to-treat analysis). In other words, the analysis attempts to
determine if the treatment works under the usual conditions,
with all of the noise inherent therein.
The overall mean and SD for the GEECT score throughout
the 844 clinical trials were 53.20 and 12.16, respectively.
The percentages of GEECT classifications are shown in
Figure 1. Approximately 44% of the trials were classified as
MEss, followed by 43.82% as MEcy. There were no
statistically significant differences between MEcy and MEss
or between HEcy and HEss (p=0.921 and p=0.052,
respectively).
A total of 735 clinical trials used the term ‘‘efficacy,’’ and
392 RCTs used the term ‘‘effectiveness.’’ Moreover, 301
clinical trials used both ‘‘efficacy’’ and ‘‘effectiveness’’ in their
published papers. In 359 clinical trials, the clinical trial
authors made appropriate use of the terms ‘‘effectiveness’’
and ‘‘efficacy’’ according to the ranking by our investigators
using the proposed GEECT score. In contrast, in 192 trials,
there was a discrepancy between the term chosen by the
authors and the investigators’ proposed GEECT score.
’ DISCUSSION
Clinical trials are indeed the best primary study design to
answer questions about treatment and prevention. Due to
their essential importance in clinical practice, there is an
Table 2 - Classification using the Grading of Efficacy-
Effectiveness in Clinical Trials (GEECT) tool.
Classification
(abbreviation)
(score range)
Definition
High Efficacy (HEcy)
(o25)
Research is very likely to apply under ideal
conditions.
Moderate Efficacy (MEcy)
(25-50)
Research is likely to apply under ideal
conditions, but certain variables are
more flexible than others (e.g., the
primary outcome is an objectively
measured, clinically meaningful outcome
for the study participants).
Moderate Effectiveness
(MEss) (51-75)
Research is likely to apply under real
conditions, but certain variables are
stricter than others (e.g., study
individuals are followed via many, more
frequent visits and more extensive data
collection than would occur in routine
practice).
High Effectiveness (HEss)
(o75)
Research is very likely to apply under real
conditions.
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urgent need to distinguish between effectiveness and efficacy
so that health professionals and policy makers can ade-
quately use the findings of trials in their respective settings.
The first tool to evaluate whether an RCT’s results would
work under ideal or real conditions was developed by
Thorpe and colleagues (5). After that tool was developed,
further studies were published with the aim of determining
the extent of the usefulness of the PRECIS tool, as one of the
major problems encountered with the tool developed by
Thorpe and colleagues was its highly subjective approach.
In the present study, the highest mean value (6.38)
presented throughout the 844 trials analyzed was for the
domain ‘‘the analysis includes all patients regardless of
compliance, eligibility, and other factors,’’ suggesting a
gradient with a tendency toward effectiveness. Meanwhile,
the lowest mean value (4.08) was related to the domain
‘‘instructions on how to apply the experimental intervention
are highly flexible,’’ which offers practitioners considerable
leeway in deciding how to formulate and apply an
intervention.
Overall, the trials were classified between MEss and MEcy,
which indicates that few trials are ‘‘purely’’ effective or
‘‘purely’’ efficacious and confirms the existence of a gradient
between the real and the desired worlds in the results of
clinical trials.
Our kappa value showed the difficulties in grading any
RCT with regard to a desired- or real-world scenario. Even
adding a score ranging from 0 (more efficacious/ideal/
desired) to 10 (more effective/real) to each of the 10 domains
of the PRECIS (5) tool, such as eligibility criteria, follow-up,
and adherence to the study protocol, did not make the new
proposed tool more objective. In fact, it is still very difficult to
rate each domain of a clinical trial and to try to distinguish
between real- and desired-world results.
One study (6) described the use of the PRECIS tool in
helping to resolve debates within a trial team on whether an
ongoing clinical trial of two drug treatments for a rare
blistering skin disease was more pragmatic or more
explanatory. The authors concluded that the PRECIS tool
can be used to retrospectively determine pragmatism, and
they provided several recommendations for using this tool.
Another study (7) applied the PRECIS criteria to a set
of trials and reported experience with a rating system scored
on a 0-4 scale. The authors emphasized the need for more
comprehensive reporting on PRECIS and indicated that the
criteria proposed by PRECIS’ collaborators may not be sufficient
to provide a precise profile of a clinical trial’s applications.
In 2011, Koppenaal et al. (8) modified the PRECIS tool
(generating the PRECIS-Review tool) to grade individual
trials and systematic reviews of trials. The trials included in
two systematic reviews were specifically scored on the 10
PRECIS domains on a scale of 1-5. The authors concluded
that the modified PRECIS tool with a 1-5 scale is less
subjective for researchers and policy makers.
Furthermore, Riddle (9) and colleagues described the
usefulness of the PRECIS tool to facilitate discussion and
decisions regarding the pragmatic-explanatory continuum-
related issues arising from a clinical trial’s results. The
researchers found that the PRECIS tool was useful in aiding
discussions related to trial design, revisions to clinical trial
design and achievement of consensus.
Additionally, a 2012 study (10) added a 20-point numerical
rating scale to the PRECIS tool to assist in the design of a
particular trial focused on smoking cessation. After discus-
sion, the authors concluded that there was consensus on all
10 domains of the study design, and the study scored high
on pragmatism.
Although we have proposed a quantitative score in an
attempt to reduce subjectivity, we feel that this is still not
sufficient, as there might be a tendency to grade toward the
central value if investigators are unclear on how to proceed
with the score. Furthermore, the clinical expertise of the
investigator seems to make a difference in how each domain
of the modified PRECIS tool is ranked, as indicated by the
finding of slight agreement in the kappa test in the current
study. Another issue is the lack of information reported in the
RCTs examined in the present study, which made it even
more difficult to rank them from 0-10.
Moreover, when an RCT reported on both intention-to-
treat and per-protocol analyses, we gave it a score of five, but
this method introduced bias into the final GEECT score and
most likely affected the RCT’s classification.
Even though we encountered these issues, RCTs’ authors
should be encouraged to explore these tools when designing
their studies, and policy makers can use the existing tools
while further instruments to reduce the subjectivity of such
tools are under investigation.
Loudon et al. (11) proposed a study to improve and
validate a version of the PRECIS tool and to compare the
internal validities of a set of explanatory and pragmatic trials
matched by intervention.
Furthermore, there is another prominent approach to this
problem, which is termed ‘‘pragmatic-mechanistic’’ (12,13).
In particular, authors have proposed a new mechanistic-
practical framework for designing and interpreting RCTs
because they believe that there are major limitations (such
as confusing purpose with structure) to the interpretation of
the explanatory-pragmatic framework. However, several
authors do not agree with how these arguments were
framed, but they recognize that the mechanists have
identified an important problem: how pragmatic a trial is
depends on one’s perspective and context (14).
The GEECT classification based on the 0-100 score is still
highly subjective and can be easily misunderstood in all of
the domains based on each investigator’s own experiences,
knowledge, and values. However, we found the following
with respect to the clinical trials in the literature over the last
three years:
Figure 1 - The Grading of Efficacy-Effectiveness in Clinical Trials
(GEECT) classification throughout the 844 clinical trials analyzed.
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All of the clinical trials published in the last three years
that we analyzed did not use the criteria proposed by the
PRECIS tool to differentiate between the real and the desired
worlds.
The majority of the clinical trials’ authors made appropriate
use of the terms ‘‘effectiveness’’ and ‘‘efficacy’’ according to
the rankings by our investigators using the GEECT scale, but
the relatively common use of both terms (effectiveness and
efficacy) in the same publication makes it difficult to use the
scale in the development of health policies.
 The majority of the trials studied were classified as MEss/
real world (51-75), followed by MEcy/desired world
(25-50), according to the GEECT tool.
 Most clinical trials published in the analyzed journals in
the last three years used the term ‘‘efficacy’’ to illustrate the
application of results in clinical practice.
More research is needed to establish the easiest and most
useful tool to a) facilitate the applicability of results in clinical
practice, b) distinguish between effectiveness (real world)
and efficacy (desired world) results and c) assist researchers
in preparing and planning clinical trials.
We also suggest that after the establishment of a more
appropriate and objective tool to determine the specific
application of a clinical trial’s results (i.e., more effective or
more efficacious), journals all over the world that publish
clinical trials should request the submission of a quantitative
score related to effectiveness or efficacy by authors, along
with their full research articles. Furthermore, journals should
publish a note with regard to the effectiveness and efficacy
scores that accompany the main text of a clinical trial.
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